Overview Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection Status: Completed Trial end date: 2020-03-23 Target enrollment: Participant gender: Summary The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment. Phase: Phase 2 Details Lead Sponsor: Atea Pharmaceuticals, Inc.